Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wellbutrin XL TV Ad References Suicidality In Children, Adolescents

This article was originally published in The Pink Sheet Daily

Executive Summary

Revamped "product and use" commercial does not reflect full text of the new "black box" class warning for all antidepressants. GlaxoSmithKline also is running a print ad. The company says it precleared the ads with FDA's ad review division.

You may also be interested in...



Cymbalta Study Shows Less Male Sexual Dysfunction Than Lexapro

Lilly post-market study finds 37% of men treated with duloxetine experienced sexual worsening, compared with 59% for Forest’s Lexapro.

Cymbalta Study Shows Less Male Sexual Dysfunction Than Lexapro

Lilly post-market study finds 37% of men treated with duloxetine experienced sexual worsening, compared with 59% for Forest’s Lexapro.

Pfizer Zoloft Ad Cited By FDA For Omitting Suicide Risk

FDA's ad review division objects to an October print ad for the antidepressant that failed to mention the risk of suicidality and clinical worsening. The ad's brief summary referenced information from outdated labeling, the agency says.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel